Florida Cancer Specialists - East West Palm Beach, FL (SCRI)
Welcome,         Profile    Billing    Logout  
 4 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abesada-Terk, Guillermo
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Completed
3
56
US
ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
06/23
06/24
McCune, Steve
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
Vattigunta, Sumithra
DENALI, NCT05128825: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
2
170
Europe, US, RoW
azenosertib, ZN-c3
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
12/26
06/27
Berman, Barry S
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
Koshkin, Vadim
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
43
Europe, US
futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04
Taiho Oncology, Inc., Merck Sharp & Dohme LLC
Advanced and Metastatic Urothelial Cancer
03/24
08/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
NCT06470282: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Recruiting
1/2
47
US
Enfortumab Vedotin, Padcev, Pembrolizumab, Keytruda, Intensity Modulated Radiation Therapy (IMRT), Standard of care IMRT, Transurethral Resection of Bladder Tumor, Transurethral resection (TURBT), Cystoscopy (CS), CS, Computed Tomography (CT), CT Scan, Magnetic Resonance Imaging (MRI), MRI Scan, Positron Emission Tomography (PET), PET Scan
University of California, San Francisco, Astellas Pharma Inc, Merck Sharp & Dohme LLC
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
01/28
01/28
UPLIFT, NCT05113537: Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Recruiting
1/2
30
US
Abemaciclib, Abemaciclib Oral, LY-2835219, Verzenio, Lutetium Lu 177-PSMA-617, 177Lu-labeled PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan
Vadim S Koshkin, Prostate Cancer Foundation, Eli Lilly and Company
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
12/25
07/27
NCT05902494: HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Recruiting
N/A
350
Europe, US
Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma
07/25
07/25
Coyle, Luke
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
Sadawarte, Sonali
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abesada-Terk, Guillermo
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Completed
3
56
US
ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
06/23
06/24
McCune, Steve
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
Vattigunta, Sumithra
DENALI, NCT05128825: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
2
170
Europe, US, RoW
azenosertib, ZN-c3
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
12/26
06/27
Berman, Barry S
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
Koshkin, Vadim
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
43
Europe, US
futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04
Taiho Oncology, Inc., Merck Sharp & Dohme LLC
Advanced and Metastatic Urothelial Cancer
03/24
08/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Urothelial Carcinoma
12/26
06/28
NCT06470282: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Recruiting
1/2
47
US
Enfortumab Vedotin, Padcev, Pembrolizumab, Keytruda, Intensity Modulated Radiation Therapy (IMRT), Standard of care IMRT, Transurethral Resection of Bladder Tumor, Transurethral resection (TURBT), Cystoscopy (CS), CS, Computed Tomography (CT), CT Scan, Magnetic Resonance Imaging (MRI), MRI Scan, Positron Emission Tomography (PET), PET Scan
University of California, San Francisco, Astellas Pharma Inc, Merck Sharp & Dohme LLC
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
01/28
01/28
UPLIFT, NCT05113537: Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Recruiting
1/2
30
US
Abemaciclib, Abemaciclib Oral, LY-2835219, Verzenio, Lutetium Lu 177-PSMA-617, 177Lu-labeled PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan
Vadim S Koshkin, Prostate Cancer Foundation, Eli Lilly and Company
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
12/25
07/27
NCT05902494: HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Recruiting
N/A
350
Europe, US
Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma
07/25
07/25
Coyle, Luke
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
Sadawarte, Sonali
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25

Download Options